文献速递细菌感染、耐药与抗菌药物

肠杆菌科菌血症降阶梯治疗对预后影响的多中心前瞻性队列事后分析

Impact of De-escalation on Prognosis of Patients With Bacteremia due to Enterobacteriaceae: A Post Hoc Analysis From a Multicenter Prospective Cohort.
PubMed 文献 · Clin Infect Dis · 2019-01-01

本研究对516例肠杆菌科血流感染患者进行事前设计的多中心前瞻性队列事后分析,其中早期降阶梯241例(46%)、晚期降阶梯95例(18%)、未降阶梯180例(35%)。多药耐药分离株和院内感染经验性使用亚胺培南或美罗培南与早期降阶梯概率降低独立相关;控制混杂因素后,早期降阶梯与30天全因死亡率升高无关,降阶梯与临床失败或住院时间也无关联。

要点

  • 肠杆菌科菌血症降阶梯治疗未增加30天全因死亡率。
  • 多药耐药菌株和院内感染经验性使用碳青霉烯类降低早期降阶梯概率。
  • 降阶梯与临床失败及住院时间延长无关。

核心结论

  • 对肠杆菌科单微生物菌血症患者,降阶梯治疗与临床结局无不利影响。

研究设计与样本

  • 多中心前瞻性队列的事后分析,纳入516例初始接受厄他培南或抗假单胞菌β-内酰胺类治疗的肠杆菌科血流感染患者。
  • 采用logistic回归分析早期降阶梯相关因素,Cox回归分析早期和晚期降阶梯对30天全因死亡率的影响,并计算倾向评分。
  • 同时分析治疗结束时失败率和住院时间。

主要发现

  • 早期降阶梯241例(46%),晚期降阶梯95例(18%),未降阶梯180例(35%)。
  • 晚期降阶梯与死亡率无关,降阶梯与临床失败或住院时间无关。

临床怎么用

  • 对肠杆菌科菌血症患者可考虑降阶梯治疗以缩小抗菌谱,未观察到死亡风险增加。
  • 多药耐药菌株或院内感染经验性使用碳青霉烯类者早期降阶梯可能性较低,需个体化评估。

局限性

  • 为事后分析,可能存在未控制混杂。
  • 仅纳入初始接受厄他培南或抗假单胞菌β-内酰胺类治疗的患者,外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: More data are needed about the safety of antibiotic de-escalation in specific clinical situations as a strategy to reduce exposure to broad-spectrum antibiotics. The aims of this study were to investigate predictors of de-escalation and its impact on the outcome of patients with bloodstream infection due to Enterobacteriaceae (BSI-E). METHODS: A post hoc analysis was performed on a prospective, multicenter cohort of patients with BSI-E initially treated with ertapenem or antipseudomonal β-lactams. Logistic regression was used to analyze factors associated with early de-escalation (EDE) and Cox regression for the impact of EDE and late de-escalation (LDE) on 30-day all-cause mortality. A propensity score (PS) for EDE vs no de-escalation (NDE) was calculated. Failure at end of treatment and length of hospital stay were also analyzed. RESULTS: Overall, 516 patients were included. EDE was performed in 241 patients (46%), LDE in 95 (18%), and NDE in 180 (35%). Variables independently associated with a lower probability of EDE were multidrug-resistant isolates (odds ratio [OR], 0.50 [95% confidence interval {CI}, .30-.83]) and nosocomial infection empirically treated with imipenem or meropenem (OR, 0.35 [95% CI, .14-.87]). After controlling for confounders, EDE was not associated with increased risk of mortality; hazard ratios (HR) (95% CIs) were as follows: general model, 0.58 (.25-1.31); model with PS, 0.69 (.29-1.65); and PS-based matched pairs, 0.98 (.76-1.26). LDE was not associated with mortality. De-escalation was not associated with clinical failure or length of hospital stay. CONCLUSIONS: De-escalation in patients with monomicrobial bacteremia due to Enterobacteriaceae was not associated with a detrimental impact on clinical outcome.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Palacios-Baena ZR, Delgado-Valverde M, Valiente Méndez A, et al. Impact of De-escalation on Prognosis of Patients With Bacteremia due to Enterobacteriaceae: A Post Hoc Analysis From a Multicenter Prospective Cohort. Clin Infect Dis. 2019. PMID: 30535051. doi:10.1093/cid/ciy1032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。